BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 2,695 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $25.44, for a total value of $68,560.80. Following the transaction, the insider now owns 43,165 shares in the company, valued at approximately $1,098,117.60. This trade represents a 5.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Sarah Aebersold also recently made the following trade(s):
- On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The stock was sold at an average price of $24.96, for a total transaction of $140,574.72.
- On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total value of $27,275.00.
- On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $6,484.80.
BioLife Solutions Stock Performance
Shares of BLFS stock traded down $0.07 during trading on Friday, reaching $24.99. 569,608 shares of the company's stock traded hands, compared to its average volume of 350,621. The firm's 50-day moving average is $26.40 and its 200 day moving average is $25.49. The company has a market capitalization of $1.17 billion, a P/E ratio of -23.58 and a beta of 2.04. BioLife Solutions, Inc. has a 1 year low of $14.84 and a 1 year high of $29.55. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same quarter in the prior year, the business posted ($0.21) earnings per share. Equities research analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on BLFS shares. Benchmark reaffirmed a "buy" rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. StockNews.com upgraded shares of BioLife Solutions from a "sell" rating to a "hold" rating in a report on Wednesday. KeyCorp boosted their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research note on Friday, December 13th. HC Wainwright raised their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Finally, Northland Securities upped their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $29.86.
Read Our Latest Stock Report on BLFS
Institutional Investors Weigh In On BioLife Solutions
Several hedge funds and other institutional investors have recently modified their holdings of BLFS. Steward Partners Investment Advisory LLC purchased a new position in BioLife Solutions during the fourth quarter valued at approximately $26,000. Mark Sheptoff Financial Planning LLC bought a new position in BioLife Solutions in the 3rd quarter valued at $28,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of BioLife Solutions during the 4th quarter valued at $31,000. Quest Partners LLC bought a new position in shares of BioLife Solutions in the third quarter worth $57,000. Finally, 1620 Investment Advisors Inc. raised its position in shares of BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after buying an additional 675 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors.
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Stories
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
